Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fast dosiskombination af DESloratadin / PREDnisolon i behandling. af moderat - svær allergisk rhinitis hos børn (DESPRED)

22. oktober 2026 opdateret af: Eurofarma Laboratorios S.A.

Multicenter, randomiseret, parallel, dobbeltblind, sammenlignende undersøgelse af overlegenheden af ​​FDC af Desloratadin 0,5 mg/ml og Prednisolon 4 mg/ml versus desloratadin 0,5 mg/ml i behandling. af vedvarende allergisk rhinitis hos børn

Multicenter, randomized, parallel-group, double-blind, double-dummy, comparative clinical trial of the superiority of the fixed-dose combination of desloratadine 0.5 mg/mL and prednisolone 4 mg/mL from Eurofarma Laboratórios SA versus desloratadine 0.5 mg/mL in the treatment of moderate to severe persistent allergic rhinitis in children aged 6 to 12 years.

⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

Desloratadine and prednisolone are active pharmaceutical ingredients (APIs) already registered in the country as monodrugs. These products are widely used and their efficacy and safety are well known in daily clinical practice in the approved indications.

Once confirmed the absence of pharmacokinetic interaction between desloratadine and prednisolone in relative bioavailability studies, this phase 3 study will be conducted with the objective of demonstrating the superiority of the new FDC containing desloratadine and prednisolone over the isolated administration of desloratadine in treatment from moderate to severe allergic rhinitis in children. The aim is to provide a new effective, safe and well-tolerated therapeutic option for dealing with these cases.

Multicenter, randomized, parallel group, double blind, double-dummy, superiority comparative clinical trial.

Children aged ≥ 6 years and < 12 years with moderate to severe persistent allergic rhinitis unresponsive to optimal treatment, including daily use of intranasal corticosteroids, will be randomized in a 1:1 ratio to receive FDC desloratadine 0.5mg/mL/prednisolone 4mg/mL - gel for oral administration by Eurofarma Laboratórios SA (experimental drug) or desloratadine 0.5mg/mL - syrup, for five (05) days.

⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

262

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • São Paulo, Brasilien
        • Eurofarma Laboratorios S.A

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 år til 12 år (Barn)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 6 years and ≤ 12 years.
  2. Diagnosis of moderate to severe persistent allergic rhinitis (PAR) according to ARIA (Allergic Rhinitis and Its Impact on Asthma) criteria.
  3. Sensitization to aeroallergens confirmed by the presence of a positive result on the immediate skin test (PRICK test) and/or by the presence of specific IgE.
  4. Total nasal symptom score (TNSS ) ≥ 8 points.
  5. Symptom intensity score "nasal obstruction" ≥ 2 points.
  6. Signing of the Informed Consent Form (ICF) by the legal guardian and the Informed Assent Form (IAF) before performing any study procedure.

Exclusion Criteria:

  1. Being using or having an indication for antibiotic therapy upon selection for the study.
  2. Use of prednisolone or other oral corticosteroids in the last seven (07) days.
  3. Presence of uncontrolled asthma.
  4. Covid-19 diagnosis within four (04) weeks prior to randomization.
  5. Positive for SARS-COV-2 rapid antigen test at the time of randomization.
  6. Known allergy to desloratadine, prednisolone or any component of the product formulations under investigation.
  7. Presence of systemic fungal infections or uncontrolled infections.
  8. Presence of any serious or uncontrolled diseases, at the investigator's discretion.
  9. Presence of pregnancy or lactation.
  10. At the discretion of the investigator, female participants who are already of childbearing age must confirm the use of contraception or expressly declare that they are not at risk of pregnancy because they do not engage in sexual practices or do so in a non-reproductive manner.
  11. Participation in a clinical research protocol in the last 6 months, unless, according to the investigator's criteria, their participation in the study could imply a direct benefit for the participant.
  12. Presence of any condition that, at the investigator's discretion, renders the patient unfit to participate in the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental drug (Desloratadine 0.5 mg/mL/Prednisolone 4 mg/mL)

ADF Group 1 - Eurofarma drug association of Desloratadine 0.5 mg/mL / Prednisolone 4 mg/mL

FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA

Aktiv komparator: Active Comparator: Desalex® (Desloratadine 0.5 mg/mL)

Desalex® Group 2 - Eurofarma drug Desloratadine 0.5 mg/mL

Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The total nasal symptom score (TNSS)
Tidsramme: five (05) days after the treatment start

Primary objective: Demonstrate the superiority of the experimental drug (FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA) compared to desloratadine 0.5 mg/mL in alleviating symptoms of moderate/severe allergic rhinitis in children through the absolute variation of the total nasal symptom score (TNSS) five (05) days after the treatment start. The TNSS is determined by the sum of the intensity scores attributed to the symptoms of nasal obstruction, runny nose, nasal itching and sneezing in the last 24 hours. Each symptom is assessed using a 4-point categorical scale (0=absent symptom, 1=mild symptom, 2=moderate symptom, 3=intense symptom).

five (05) days after the treatment start

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The total nasal symptom score (TNSS) ( efficacy)
Tidsramme: three (03) days after the treatment start

Secondary objectives: To compare the efficacy of the experimental drug (FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA) against desloratadine 0.5 mg/mL in alleviating symptoms of moderate/severe allergic rhinitis in children through TNSS. The TNSS is determined by the sum of the intensity scores attributed to the symptoms of nasal obstruction, runny nose, nasal itching and sneezing in the last 24 hours. Each symptom is assessed using a 4-point categorical scale (0=absent symptom, 1=mild symptom, 2=moderate symptom, 3=intense symptom).

three (03) days after the treatment start

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. juli 2024

Primær færdiggørelse (Faktiske)

23. marts 2025

Studieafslutning (Faktiske)

23. marts 2025

Datoer for studieregistrering

Først indsendt

13. december 2021

Først indsendt, der opfyldte QC-kriterier

28. januar 2022

Først opslået (Faktiske)

31. januar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner